Indonesia

Population 2017: 264 million

### Tuberculosis Profile

#### Estimates of TB burden*, 2017

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>110 (100–110)</td>
<td>40 (38–43)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>9.3 (4.9–15)</td>
<td>3.5 (1.9–5.7)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>842 (767–919)</td>
<td>319 (291–348)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>36 (20–56)</td>
<td>14 (7.6–21)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>23 (16–31)</td>
<td>8.8 (6.2–12)</td>
</tr>
</tbody>
</table>

#### Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>23 (20–26)</td>
<td>26 (23–30)</td>
<td>49 (45–54)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>326 (283–370)</td>
<td>466 (404–528)</td>
<td>792 (717–868)</td>
</tr>
<tr>
<td>Total</td>
<td>349 (305–393)</td>
<td>492 (430–554)</td>
<td>842 (767–919)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2017

- Total cases notified: 447,106
- Total new and relapse: 442,172
- % tested with rapid diagnostics at time of diagnosis: 2%
- % with known HIV status: 29%
- % pulmonary: 90%
- % bacteriologically confirmed among pulmonary: 54%

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 53% (48–58)
- TB patients facing catastrophic total costs: 0.14 (0.12–0.15)
- TB/HIV care in new and relapse TB patients, 2017: 7,729 (6%)
- on antiretroviral therapy: 2,244 (29%)

#### Drug-resistant TB care, 2017

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 12,000 (8,700–15,000)
- Estimated % of TB cases with MDR/RR-TB: 2.4% (1.8–3.3) & 13% (9–18)
- % notified tested for rifampicin resistance: 16% & 219% (112,743)
- MDR/RR-TB cases tested for resistance to second-line drugs: 1,813
- Laboratory-confirmed cases: MDR/RR-TB: 5,070, XDR-TB: 51
- Patients started on treatment ****: MDR/RR-TB: 3,042, XDR-TB: 50

#### Treatment success rate and cohort size

- New and relapse cases registered in 2016: 86% (364,671)
- Previously treated cases, excluding relapse, registered in 2016: 71% (2,002)
- HIV-positive TB cases registered in 2016: 64% (4,470)
- MDR/RR-TB cases started on second-line treatment in 2015: 47% (1,565)
- XDR-TB cases started on second-line treatment in 2015: 28% (32)

#### TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 16%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 8.5% (7.8–9.3)

#### TB financing, 2018

- National TB budget (US$ millions): 294

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed